Recent advances in biology and genetics have provided companies with a wealth of new science and targets in which to target, and hopefully, successfully treat cancer. Our panelists represent leaders at companies that are at the forefront of completely new mechanism of action in oncology, including oxidative stress (which is in Ph3 trials), epigenetics, cancer metabolism and enzyme inhibition.

• Provide insight in exploring these new mechanisms and the potential they represent from a therapeutic standpoint
• Discuss current information and understanding about the MOAs, their current development status and available data
• Review a biological background and origins of each MOA